Skip to content

The effectiveness and safety of Anjianning(adalimumab) for the treatment of autoimmune diseases in the real-world: A multicenter, prospective, observational study

The effectiveness and safety of Anjianning(adalimumab) for the treatment of autoimmune diseases in the real-world: A multicenter, prospective, observational study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104254
Enrollment
Unknown
Registered
2025-06-13
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis)

Interventions

RA group:NA
AS group:NA
PsO group:NA

Sponsors

ShangHai GuangHua Hospital of Integrated Traditiona.Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. voluntarily signed informed consent; 2. met any of the following disease classification criteria: (1) 1987 ACR classification criteria for RA or 2010 ACR/EULAR classification criteria for RA; (2) met 1984 New York modified AS diagnostic criteria; (3) clinically confirmed PsO; 3. aged greater than or equal to 18 years; 4. prepared or started using Anjianning ®.

Exclusion criteria

Exclusion criteria: 1. active tuberculosis or other serious infectious diseases; 2. moderate to severe heart failure (New York Heart Association grade 3-4); 3. allergic to the ingredients of this product.

Design outcomes

Primary

MeasureTime frame
Proportion of patients achieving ACR 20;Proportion of patients achieving ASAS 20;Proportion of patients achieving PASI 75;Incidence and types of adverse reactions;

Countries

China

Contacts

Public ContactHe Dongyi

Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine

dongyihe@medmail.com.cn+86 158 0030 0800

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026